Acute Pain Model Development Services
Acute pain is an immediate and protective physiological response to tissue injury, inflammation, or noxious stimuli. Understanding and modulating acute pain through reliable preclinical models is critical in the early phases of analgesic drug development. At Ace Therapeutics, we specialize in developing and implementing robust in vivo acute pain models to support our partners in their preclinical analgesic programs. Our services are designed to evaluate drug efficacy, explore dose–response relationships, investigate mechanisms of action, and assess safety and pharmacokinetics.
Acute pain is typically short-lived, lasting hours to days, and results from tissue injury, surgical procedures, or inflammation. Unlike chronic pain, acute pain usually resolves as the underlying cause heals. Despite its transient nature, acute pain requires precise pharmacological intervention to prevent complications and improve recovery. Preclinical models play a vital role in simulating human acute pain conditions, enabling researchers to test the pharmacodynamics, potency, and safety of candidate analgesics under controlled conditions.
Ace Therapeutics offers validated acute pain models representing a range of pain-inducing mechanisms. These models mimic human conditions associated with acute pain and are optimized for reproducibility, sensitivity, and translational relevance.
| Model Type | Induction Method | Applications |
| Thermal Pain Models | Hot plate, tail-flick | Nociceptive response to thermal stimuli |
| Chemical Pain Models | Acetic acid-induced writhing, formalin test | Visceral or inflammatory nociception |
| Mechanical Pain Models | Von Frey filament, pinprick stimulation | Hyperalgesia or allodynia assessment |
| Post-incisional Pain Model | Surgical incision in hind paw | Acute postoperative pain |
| Carrageenan-Induced Pain | Carrageenan injection in paw | Inflammation-associated acute pain |
Each model is supported by appropriate baseline validation data, including behavioral, biochemical, and histological endpoints where applicable.
Ace Therapeutics does not simply provide models—we deliver comprehensive downstream preclinical services using these models to support your drug development pipeline. Our service workflow is tailored to align with key stages in the analgesic drug development process.
Model Selection and Feasibility Testing
Pain Model Induction
Analgesic Efficacy and Dose Exploration
Mechanism of Action and Biomarker Analysis
Toxicology and Pharmacokinetics
Our acute pain model studies generate high-quality data suitable for IND-enabling preclinical development. Common endpoint categories include
Ace Therapeutics combines deep expertise in pain pathophysiology with cutting-edge preclinical capabilities. Our acute pain model development services deliver actionable insights to de-risk analgesic candidates. Contact us to design a tailored program for your next-generation analgesic.
What is the difference between thermal, mechanical, and chemical pain models?
Thermal models assess responses to heat stimuli; mechanical models evaluate sensitivity to pressure or touch; chemical models involve nociceptive reactions to irritants like acetic acid or formalin.
How do you assess analgesic efficacy in these models?
We use quantitative behavioral metrics (e.g., latency to withdrawal, writhing counts), along with biochemical and histological assays to assess anti-nociceptive effects.
Can I test both immediate and sustained effects of my compound?
Yes. Time-course studies can be designed to monitor analgesic effects at multiple time points post-administration.
Is customization available for unique drug mechanisms or delivery routes?
Absolutely. We tailor experimental design—including dosage, delivery, and endpoints—to fit the specific pharmacology of your compound.
Do you support combination therapy studies?
Yes, we can assess drug combinations to explore synergistic or additive effects in acute pain models.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics comprises a team of highly committed and skilled researchers focused exclusively on providing innovative preclinical contract research solutions for novel analgesic development. We deliver rigorous models and data essential for advancing targeted, non-addictive pain therapies toward clinical evaluation.